Compound News and Research

RSS

Botox reduces short-term pain in thoracic outlet syndrome patients

Made popular for its ability to smooth wrinkles when injected into the face, Botox - a toxin known to weaken or paralyze certain nerves and muscles - may have another use that goes beyond the cosmetic.

11 Jun 2010

LAB Research completes development of novel drug investigation model

LAB Research Inc., a Canadian-based global non-clinical contract research organization, today announced that it has recently completed development of a novel drug investigation model focused on biodistribution and pharmacokinetic of biologics.

10 Jun 2010

Updated clinical data from SNSS's Phase 2 clinical trial of voreloxin

MicroStockProfit.com announces an investment report featuring Sunesis Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

10 Jun 2010

Study suggests potential of ARC man-made compound in combination with Abbott's ABT-737 for cancer

Adding a second agent may make a new, experimental anti-cancer drug effective against a wide range of cancers, researchers at the University of Illinois at Chicago College of Medicine have found.

10 Jun 2010

Scientists discover how polyphenols present in red wine and green tea inhibit prostate cancer growth

In what could lead to a major advance in the treatment of prostate cancer, scientists now know exactly why polyphenols in red wine and green tea inhibit cancer growth. This new discovery, published online in The FASEB Journal, explains how antioxidants in red wine and green tea produce a combined effect to disrupt an important cell signaling pathway necessary for prostate cancer growth.

10 Jun 2010

NIH awards Aestus $2M SBIR grant for clinical trials of treatment for chronic neuropathic pain

Aestus Therapeutics, Inc. announced that it has been awarded a $2 million Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH). The grant, from the NIH's National Institute of Neurological Disorders and Stroke (NINDS), will fund clinical trials of Aestus's novel, first-in-class treatment for chronic neuropathic pain.

9 Jun 2010

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

S*BIO Pte Ltd today announced that it has completed enrollment of patients in two separate Phase 2 clinical trials for its potent and orally-active JAK2 inhibitor SB1518 at multiple clinical sites in the U.S. and Australia for the treatment of myelofibrosis (MF).

9 Jun 2010

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Repligen Corporation today reported results for the fourth quarter and fiscal year 2010, ended March 31, 2010. Total revenue for the year was $20,971,000 compared to total revenue of $29,362,000 for fiscal year 2009 ended March 31, 2009.

9 Jun 2010

CXCR4 protein restores brain damage in multiple sclerosis patients

A protein that helps build the brain in infants and children may aid efforts to restore damage from multiple sclerosis (MS) and other neurodegenerative diseases, researchers at Washington University School of Medicine in St. Louis have found.

9 Jun 2010

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.

9 Jun 2010

DSM commences cGMP-manufacturing of Novacta's C. difficile compound

DSM BioSolutions today announced that it has entered into an agreement with Novacta Biosystems Limited, Welwyn Garden City, UK, for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds.

9 Jun 2010

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

GE Healthcare, a unit of the General Electric Company, today will present results of a phase 1 study of anti-[18F]FACBC at the 57th annual meeting of the Society of Nuclear Medicine in Salt Lake City, Utah. The presentation closely follows the launch of the phase 2 clinical development program for anti-[18F]FACBC, which was initially discovered and developed by Emory University, Atlanta, Georgia, and was licensed to Nihon Medi-Physics Co., Ltd. (NMP) of Japan.

9 Jun 2010

Experimental drug ipilimumab increases overall survival in patients with metastatic melanoma: Study

The Melanoma Network of Canada is excited with the new hope that long-anticipated results of a late-stage skin cancer trial brings to patients with advanced melanoma. The results, presented at the American Society of Clinical Oncology annual meeting, show increased survival with the experimental treatment ipilimumab in patients with previously-treated metastatic melanoma, the most deadly form of skin cancer.

9 Jun 2010

PharmaMar commences Aplidin Phase III registration trial for multiple myeloma

PharmaMar SA today announced that a registration trial in relapsed/refractory multiple myeloma patients has been initiated with Aplidin(R) (plitidepsin) in combination with dexamethasone versus dexamethasone alone.

9 Jun 2010

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

TransTech Pharma, Inc and Forest Laboratories, Inc., today announced that TransTech Pharma and Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. have entered into a license agreement for the development and commercialization of small molecule compounds discovered and developed by TransTech Pharma.

9 Jun 2010

Aerovance reports top-line results from Aerovant Phase 2b clinical trial for eosinophilic asthma

Aerovance Inc. today announced top-line results from its Phase 2b clinical trial that show the inhaled dry powder formulation of Aerovant (pitrakinra inhalation powder) is effective in a pre-defined subset of patients with eosinophilic asthma.

8 Jun 2010

CXCR4 protein may aid restore damage from MS and other neurodegenerative diseases: Researchers

A protein that helps build the brain in infants and children may aid efforts to restore damage from multiple sclerosis and other neurodegenerative diseases, researchers at Washington University School of Medicine in St. Louis have found.

8 Jun 2010

Research findings open door to development of new therapies for lymphomas, leukemias

Scripps Research Institute scientists have discovered a new way to target and destroy a type of cancerous cell. The findings may lead to the development of new therapies to treat lymphomas, leukemias, and related cancers.

8 Jun 2010

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Synta Pharmaceuticals Corp. announced that clinical results for two Phase 1 trials of STA-9090 in solid tumors, as well as 12 month updated survival results from the SYMMETRY trial of elesclomol in metastatic melanoma, were presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).

8 Jun 2010

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened Investigational New Drug application (IND) with the United States Food and Drug Administration (US FDA). The IND is for Can-Fite's lead compound, CF101, for the treatment of patients with psoriasis. This is the third US IND for CF101, and the fourth for Can-Fite.

8 Jun 2010

Compound News and Research

Botox reduces short-term pain in thoracic outlet syndrome patients

LAB Research completes development of novel drug investigation model

Updated clinical data from SNSS's Phase 2 clinical trial of voreloxin

Study suggests potential of ARC man-made compound in combination with Abbott's ABT-737 for cancer

Scientists discover how polyphenols present in red wine and green tea inhibit prostate cancer growth

NIH awards Aestus $2M SBIR grant for clinical trials of treatment for chronic neuropathic pain

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

Repligen's fiscal 2010 total revenue decreases to $20,971,000

CXCR4 protein restores brain damage in multiple sclerosis patients

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

DSM commences cGMP-manufacturing of Novacta's C. difficile compound

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

Experimental drug ipilimumab increases overall survival in patients with metastatic melanoma: Study

PharmaMar commences Aplidin Phase III registration trial for multiple myeloma

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

Aerovance reports top-line results from Aerovant Phase 2b clinical trial for eosinophilic asthma

CXCR4 protein may aid restore damage from MS and other neurodegenerative diseases: Researchers

Research findings open door to development of new therapies for lymphomas, leukemias

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News